

Kristen A Batich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6558657/publications.pdf>

Version: 2024-02-01

23
papers

1,332
citations

840776

11
h-index

888059

17
g-index

23
all docs

23
docs citations

23
times ranked

2128
citing authors

#	ARTICLE	IF	CITATIONS
1	Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. <i>Nature</i> , 2015, 519, 366-369.	27.8	429
2	The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists. <i>Cancer Research</i> , 2017, 77, 1783-1812.	0.9	270
3	Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. <i>Clinical Cancer Research</i> , 2017, 23, 1898-1909.	7.0	215
4	Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 1049-1060.	3.0	84
5	Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. <i>Cancer Research</i> , 2018, 78, 256-264.	0.9	82
6	Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma. <i>Oncotarget</i> , 2018, 9, e1434464.	4.6	69
7	Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 5297-5303.	7.0	67
8	Emerging immunotherapies for glioblastoma. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 133-145.	2.4	34
9	Operative and perioperative considerations in the management of brain metastasis. <i>Cancer Medicine</i> , 2019, 8, 6809-6831.	2.8	28
10	Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2047-2061.	1.8	19
11	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 585-593.	7.0	18
12	Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy. <i>Methods in Molecular Biology</i> , 2016, 1403, 819-838.	0.9	5
13	Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma. <i>Oncotarget</i> , 2022, 13, 576-582.	1.8	4
14	INN-20. RADIOGRAPHIC RESPONSE AND SEIZURE CONTROL IN IDH1 MUTANT GLIOMA PATIENTS USING IVOSIDENIB. <i>Neuro-Oncology</i> , 2021, 23, vi109-vi109.	1.2	3
15	CTIM-10. REPRODUCIBILITY OF CLINICAL TRIALS USING CMV-TARGETED DENDRITIC CELL VACCINES IN PATIENTS WITH GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi51-vi51.	1.2	2
16	Generation of Tumor Targeted Dendritic Cell Vaccines with Improved Immunogenic and Migratory Phenotype. <i>Methods in Molecular Biology</i> , 2022, 2410, 609-626.	0.9	2
17	Complete response to steroids in dural inflammatory pseudotumor associated with Stillé's disease. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 1445-1448.	1.5	1
18	Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy. , 2021, , 635-665.		0

#	ARTICLE	IF	CITATIONS
19	Control of renal cell carcinoma brain metastases with cabozantinib following progression on immune checkpoint inhibitor therapy. <i>Current Problems in Cancer Case Reports</i> , 2021, 3, 100060.	0.1	0
20	Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4533-4533.	1.6	0
21	Myeloid-derived suppressor cell (MDSC) kinetics following acalabrutinib and pembrolizumab treatment in platinum-resistant metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2018, 36, e16519-e16519.	1.6	0
22	Multidimensional flow characterization of circulating immune cells in cisplatin-resistant metastatic urothelial cancer (mUC) patients (pts) treated with pembrolizumab (P) with or without acalabrutinib (acala).. <i>Journal of Clinical Oncology</i> , 2019, 37, 357-357.	1.6	0
23	EXTH-44. SYSTEMIC CCL3 TREATMENT ENHANCES IMMUNOTHERAPY EFFICACY THROUGH IMPROVED DENDRITIC CELL MIGRATION. <i>Neuro-Oncology</i> , 2021, 23, vi173-vi173.	1.2	0